Biologics

Imagine requiring a life-saving cancer immunotherapy, autoimmune treatment, or obesity medication that demands injecting 5 millilitres of thick, viscous liquid through a needle at home—liquid so concentrated it flows like honey, taking minutes of sustained pressure to deliver whilst you hold perfectly still. This isn’t a hypothetical nightmare; it’s the rapidly approaching reality for millions

Twenty million Indians live with psoriasis, and for 80 per cent suffering moderate-to-severe plaque variants, the disease doesn’t merely affect skin—it devastates quality of life, relationships, and economic participation. Biologics have transformed what’s medically possible, delivering clearance rates unimaginable with conventional therapies, yet in India’s healthcare landscape, efficacy alone never determines what reaches patients. Cost

The biologics revolution—promising cures for cancer, genetic disorders, and autoimmune diseases—faces an unexpected executioner: not inadequate science, not manufacturing capacity, but regulatory bureaucracy. Whilst laboratories perfect cell cultures and purification cascades, drugs languish in approval pipelines for 12 to 18 months, inflating development costs by 30 to 50 per cent and postponing life-saving treatments by